X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
LP-184 is a small molecule drug candidate that is highly potent and synthetically lethal in solid tumors, harboring defects in multiple DNA damage repair and recombination pathways (HR/NER).
Lead Product(s): LP-184
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
LP-184 (Irofulven) is a small molecule drug candidate that is highly potent and synthetically lethal in solid tumors, harboring defects in multiple DNA damage repair and recombination pathways (HR/NER).
Lead Product(s): LP-184,Undisclosed
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
LP-184 is a small molecule drug candidate that is highly potent and synthetically lethal in solid tumors, harboring defects in multiple DNA damage repair and recombination pathways (HR/NER).
Lead Product(s): LP-184
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Details:
LP-184 (hydroxyureamethylacylfulvene) is a small molecule drug candidate that is highly potent and synthetically lethal in cancers, harboring defects in multiple DNA damage repair and recombination pathways (HR/NER).
Lead Product(s): LP-184
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
LP-184 is a small molecule drug candidate with a synthetically lethal mechanism of action (MoA) that preferentially damages DNA in cancer cells that harbor mutations in DNA damage repair (DDR) genes and that overexpress the enzyme PTGR1.
Lead Product(s): LP-184
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
LP-184 is a small molecule drug candidate with a synthetically lethal mechanism of action (MoA) that preferentially damages DNA in cancer cells that harbor mutations in DNA damage repair (DDR) genes and that overexpress the enzyme PTGR1.
Lead Product(s): LP-184
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
LP-184 is a next-generation alkylating agent designed to preferentially damage DNA in cancer cells that overexpress certain biomarkers or harbor mutations in DNA repair pathways.
Lead Product(s): LP-184
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2022
Details:
LP-184 is a small molecule drug candidate and next generation acylfulvene that preferentially damages DNA in cancer cells that harbor mutations in DNA damage repair (DDR) genes and that overexpress the enzyme PTGR1.
Lead Product(s): LP-184
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2022
Details:
LP-184 is a small molecule drug candidate and next generation acylfulvene that preferentially damages DNA in cancer cells that harbor mutations in DNA damage repair (DDR) genes and that overexpress the enzyme PTGR1.
Lead Product(s): LP-184
Therapeutic Area: Oncology Product Name: LP-184
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
